Origen del stent coronario: una historia de éxito entre científicos innovadores e industria biotecnológica

  1. Fernando Macaya-Ten 1
  2. Nieves Gonzalo 1
  3. Javier Escaned 1
  4. Carlos Macaya 1
  1. 1 nstituto Cardiovascular, Hospital Clínico San Carlos
Revista:
REC: Interventional Cardiology

ISSN: 2604-7276,  2604-7306

Ano de publicación: 2024

Volume: 6

Número: 4

Páxinas: 321-331

Tipo: Artigo

DOI: 10.24875/RECIC.M24000463 DIALNET GOOGLE SCHOLAR lock_openDialnet editor

Outras publicacións en: REC: Interventional Cardiology

Resumo

All cardiologists should delve into history to understand the current state of the art of their specialty. In the last century, the coronary stent was a pivotal achievement of research and biotechnological engineering. Since then, technology has advanced, and substantial improvements have been incorporated into this device, which has become the gold standard for treating coronary artery disease. This article summarizes the history of the coronary stent from its inception to the present day. The document reviews key historical and scientific milestones that have contributed to making percutaneous angioplasty a safe and highly effective procedure due to coronary stents. The evolution of the stent has been closely linked to the growth and maturation of interventional cardiology to date.

Referencias bibliográficas

  • Gaspard P, Whitin H. The History of Coronary Angioplasty. Toulouse:Europa Digital &Publishing/Europa Group;2017.
  • Gruentzig A, Myler R, Hanna E, Turina M. Coronary transluminal angioplasty (abstract). Circulation. 1977;56:84.
  • Gruentzig A. Results from coronary angioplasty and implications for the future. Am Heart J. 1982;103:779-783.
  • Gruentzig AR, King SB, Schlumpf M, Siegenthaler W. Long-term follow-up after percutaneous transluminal coronary angioplasty. The early Zurich experience. N Engl J Med.1987;316:1127-1132.
  • Navarro FA. Stent. Rev Esp Cardiol. 2018;71:694.
  • Roguin A. Stent:The Man and Word Behind the Coronary Metal Prosthesis. Circ Cardiovasc Interv.2011;4:206-209.
  • Dotter CT. Transluminally-placed coilspring endarterial tube grafts. Long-term patency in canine popliteal artery. Invest Radiol. 1969;4:329-332.
  • Sigwart U, Urban P, Golf S, et al. Emergency stenting for acute occlusion after coronary balloon angioplasty. Circulation. 1988;78:1121-1127.
  • Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987;316:701-706.
  • Sigwart U. What is a stent and where can you get one?Am J Cardiol. 1997;80:1122.
  • Serruys PW, Strauss BH, Beatt KJ, et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med.1991;324:13-17.
  • Tan C, Schatz RA. The History of Coronary Stenting. Interv Cardiol Clin. 2016;5:271-280.
  • Palmaz JC, Sibbitt RR, Reuter SR, Tio FO, Rice WJ. Expandable intraluminal graft:a preliminary study. Work in progress. Radiology. 1985;156:73-77.
  • Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994;331:496-501.
  • Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994;331:489-495.
  • Macaya C, Serruys PW, Ruygrok P, et al. Continued benefit of coronary stenting versus balloon angioplasty:one-year clinical follow-up of Benestent trial. Benestent Study Group. J Am Coll Cardiol. 1996;27:255-261.
  • George CJ, Baim DS, Brinker JA, et al. One-year follow-up of the Stent Restenosis (STRESS I) Study. Am J Cardiol. 1998;81:860-865.
  • Lansky AJ, Roubin GS, O'Shaughnessy CD, et al. Randomized comparison of GR-II stent and Palmaz-Schatz stent for elective treatment of coronary stenoses. Circulation. 2000;102:1364-1368.
  • Sirnes PA, Golf S, Myreng Y, et al. Stenting in Chronic Coronary Occlusion (SICCO):a randomized, controlled trial of adding stent implantation after successful angioplasty. J Am Coll Cardiol. 1996;28:1444-1451.
  • Versaci F, Gaspardone A, Tomai F, Crea F, Chiariello L, GioffrèPA. A comparison of coronary-artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery. N Engl J Med.1997;336:817-822.
  • Serruys PW, de Bruyne B, Carlier S, et al. Randomized comparison of primary stenting and provisional balloon angioplasty guided by flow velocity measurement. Doppler Endpoints Balloon Angioplasty Trial Europe (DEBATE) II Study Group. Circulation. 2000;102:2930-2937.
  • Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. 1999;341:1949-1956.
  • Colombo A, Hall P, Thomas J, Almagor Y, Finci L. Initial experience with the disarticulated (one-half) Palmaz-Schatz stent:a technical report. Cathet Cardiovasc Diagn. 1992;25:304-308.
  • Serruys PW, Rensing BJ. Handbook of Coronary Stents, Fourth Edition. Kentucky, USA:Taylor &Francis;2002.
  • Pache J, Kastrati A, Mehilli J, et al. Intracoronary stenting and angiographic results:strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol. 2003;41:1283-1288.
  • Colombo A, Stankovic G, Moses JW. Selection of coronary stents. J Am Coll Cardiol. 2002;40:1021-1033.
  • Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med.2001;344:1117-1124.
  • Gaspardone A, Versaci F. Coronary stenting and inflammation. Am J Cardiol. 2005;96:65L-70L.
  • Kearney M, Pieczek A, Haley L, et al. Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation. 1997;95:1998-2002.
  • SabatéM, Pimentel G, Prieto C, et al. Intracoronary brachytherapy after stenting de novo lesions in diabetic patients:results of a randomized intravascular ultrasound study. J Am Coll Cardiol. 2004;44:520-527.
  • Hobby G, Clark R, Woywodt A. A treasure from a barren island:the discovery of rapamycin. Clin Kidney J. 2022;15:1971-1972.
  • Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25:2677-2681.
  • Scheller B, Speck U, Abramjuk C, Bernhardt U, Böhm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004;11:810-814.
  • Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents:one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001;104:2007-2011.
  • Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
  • Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108:788-794.
  • Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents:an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584-2591.
  • Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans:delayed healing and late thrombotic risk. J Am Coll Cardiol.2006;48:193-202.
  • Otsuka F, Byrne RA, Yahagi K, et al. Neoatherosclerosis:overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J. 2015;36:2147-2159.
  • Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998-1008.
  • Torii S, Jinnouchi H, Sakamoto A, et al. Drug-eluting coronary stents:insights from preclinical and pathology studies. Nat Rev Cardiol. 2020;17:37-51.
  • Garg S, Serruys PW. Coronary Stents:Current Status. J Am Coll Cardiol. 2010;56:S1-S42.
  • Otsuka F, Vorpahl M, Nakano M, et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation.2014;129:211-223.
  • Taglieri N, Bruno AG, Ghetti G, et al. Target Lesion Failure With Current Drug-Eluting Stents:Evidence From a Comprehensive Network Meta-Analysis. JACC Cardiovasc Interv. 2020;13:2868-2878.
  • Madhavan MV, Howard JP, Naqvi A, et al. Long-term follow-up after ultrathin vs. 2nd-generation drug-eluting stents:a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2021;42:2643-2654.
  • Macaya F, Ryan N, Salinas P, Pocock SJ. Challenges in the Design and Interpretation of Noninferiority Trials. J Am Coll Cardiol. 2017;70:894-903.
  • Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000;102:399-404.
  • Nishio S, Kosuga K, Igaki K, et al. Long-term (>10 years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents:Igaki-Tamai stents. Circulation. 2012;125:2343-2353.
  • Serruys PW, Chevalier B, Sotomi Y, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II):a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016;388:2479-2491.
  • Ali ZA, Serruys PW, Kimura T, et al. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease:a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. Lancet. 2017;390:760-772.
  • Katagiri Y, Serruys PW, Asano T, et al. How does the failure of Absorb apply to the other bioresorbable scaffolds?An expert review of first-in-man and pivotal trials. EuroIntervention J. 2019;15:116-123.
  • Stone GW, Abizaid A, Onuma Y, et al. Effect of Technique on Outcomes Following Bioresorbable Vascular Scaffold Implantation:Analysis From the ABSORB Trials. J Am Coll Cardiol. 2017;70:2863-2874.
  • Smits PC, Chang CC, Chevalier B, et al. Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis:the COMPARE-ABSORB randomised clinical trial. EuroIntervention. 2020;16:645-653.
  • Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87-165.
  • Haude M, Wlodarczak A, van der Schaaf RJ, et al. Safety and performance of the third-generation drug-eluting resorbable coronary magnesium scaffold system in the treatment of subjects with de novo coronary artery lesions:6-month results of the prospective, multicenter BIOMAG-I first-in-human study. EClinicalMedicine. 2023;59:101940.
  • Gori T, Polimeni A, Indolfi C, Räber L, Adriaenssens T, Münzel T. Predictors of stent thrombosis and their implications for clinical practice. Nat Rev Cardiol. 2019;16:243-256.
  • Giustino G, Colombo A, Camaj A, et al. Coronary In-Stent Restenosis:JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;80:348-372.
  • Jeger RV, Eccleshall S, Wan AWA, et al. Drug-Coated Balloons for Coronary Artery Disease. JACC Cardiovasc Interv. 2020;13:1391-1402.
Fonte de datos: Dialnet